TRIAL DATA
Real-world study identifies factors predicting immunotherapy response in MSI-H/dMMR gastrointestinal cancers — ESMO Real World Data and Digital Oncology
A multicenter retrospective study of 122 patients with advanced MSI-H/dMMR (microsatellite instability-high/mismatch repair deficiency) gastrointestinal tumors treated with immune checkpoint inhibitors across eight Spanish university hospitals examined which clinical factors predict treatment outcomes. MSI-H/dMMR tumors have defects in DNA repair that make them particularly responsive to immunotherapy. The study included both colorectal cancer and non-colorectal GI cancers to understand response patterns across different tumor types.
What this means
If your tumor is MSI-H or dMMR, immunotherapy is likely to be part of your treatment plan. This real-world evidence helps doctors understand which patients benefit most. Make sure your tumor has been tested for MSI/MMR status — if it hasn't, ask your oncologist about testing.